#ASH17: How does Novartis’ Kymriah DLBCL data stack up heading straight to a CAR-T showdown with Gilead?
Novartis turned up at ASH with 6-month data for their pioneering CAR-T Kymriah that puts them on the inside track to a quick and near-certain approval for a second indication to treat DLBCL — and straight into a commercial showdown with Gilead/Kite.
Already snagged as the first indication to be OK’d for Gilead/Kite’s Yescarta, Novartis’ investigators nailed down remarkably similar efficacy data at the 6-month mark that closely mirrors their rival. But even with the matching outcomes on efficacy, Novartis’ team still feels that they have a clear marketing edge on the safety front.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.